Samsung Biologics said in a corrected filing that its subsidiary Samsung Peptide AG will acquire a stake of 100% in Swiss company PolyPeptide Group AG for cash.

According to the company filing, Samsung Biologics plans to acquire shares of PolyPeptide Group AG, a peptide CDMO company, through a tender offer by its Swiss subsidiary Samsung Peptide AG. The company put the acquisition amount at KRW 2.71 trillion and said the scheduled acquisition date has changed from November 13, 2026 to December 31, 2026. The company added that the timing and amount may vary depending on the tender offer conditions and approvals from relevant authorities.

1. 01

   The correction reflects a change in the scheduled acquisition date from November 13, 2026 to December 31, 2026.

2. 02

   The acquisition will be made through a tender offer. The company said the actual number of shares acquired and the stake ratio may vary depending on the results of the tender.

3. 03

   The company said that if the minimum tender condition, which is tenders of about 66.7% or more of the capital on a fully diluted basis, is not met, it will not buy any of the tendered shares.

4. 04

   The company said it plans to fund the tender offer amount through a rights offering and other means.

An AI model translated the Korean summary of this filing into English; every number is carried over from the Korean original. Reference information, not investment advice.

Key figures

Acquisition amount (KRW)

KRW 2.71 trillion (approx. KRW 2.7062 trillion)

Number of shares acquired

33,016,411

Stake ratio (%)

100

Percentage of total assets (%)

24.47

Scheduled acquisition date

December 31, 2026 (previously November 13, 2026)

Filing facts

Filing type

Investment

Report name

[Amended] Decision on Acquisition of Shares in Another Company (Subsidiary)

Filed

Oct 16, 2026

Receipt number

20261016800441